Maviret

(Glecaprevir/Pibrentasvir)

ApprovedSmall molecule

This drug is used to treat hepatitis C virus (HCV) infection. It works by stopping the virus from reproducing in the body, potentially curing the infection.[2] Maviret is currently approved and in use across 6 indications[4].[1]

Maviret is one of 201 small molecule programs targeting Chronic Hepatitis. It is currently in Approved.

Indications

Total Trials

Active Trials

200

Competitors

Pipeline

Status by Indication[4][1]

Indication

Chronic HepatitisActive, not recruiting

Kidney TransplantActive, not recruiting

Post-Traumatic Stress DisorderActive, not recruiting

Liver DiseaseActive, not recruiting

Hepatitis CActive, not recruiting

Hepatitis C Virus InfectionUnknown

Chronic HepatitisPhase 2/Phase 3

Active, not recruiting

Kidney TransplantApproved

Active, not recruiting

Post-Traumatic Stress DisorderPhase 2/Phase 3

Active, not recruiting

Liver DiseaseApproved

Active, not recruiting

Hepatitis CPhase 1/Phase 2

Active, not recruiting

Hepatitis C Virus InfectionPreclinical

Unknown

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

Maviret

AbbVie

Approved

8 2

PEG-Intron

Merck & Co.

Preclinical

43 3

Sovaldi

Gilead

Preclinical

34 4

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 5

Incivek

Vertex Pharmaceuticals

Preclinical

10 6

Intron a

Sanofi

Preclinical

7 7

Roferon-a

Roche

Preclinical

3 8

Medrol

Pfizer

Preclinical

1 9

Keyhole-Limpet Hemocyanin

Bristol-Myers Squibb

Preclinical

1 10

Pegintron

Merck & Co.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2/3Recruiting

Post-Traumatic Stress Disorder

NCT05637879

Q4 2027

PreclinicalRecruiting

Hepatitis C

NCT07040319

Clinical

Trials by Indication[1]

Hepatitis C8 trials

Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study

Completed· AbbVie logo

AbbVie·Phase 3·NCT02939989·33 enrolled

Treatment of Recently Acquired Hepatitis C With the 3D Regimen or G/P

Completed·KKirby Institute·Phase 3·NCT02634008·83 enrolled

Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination

Unknown status·KKirby Institute··NCT03776760·600 enrolled

Show 5 more trials

Utilization of Hepatitis C Positive Kidneys in Negative Recipients

Completed·OOhio State University·Phase 2/3·NCT03801707·54 enrolled

Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB)

Completed· AbbVie logo

AbbVie·Phase 3·NCT04903626·286 enrolled

Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

Unknown status·KKirby Institute·N/A·NCT03981211·60 enrolled

Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ Donor

Completed·UUniversity of California, San Diego·Phase 1/2·NCT04596475·12 enrolled

Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women With Hepatitis C With and Without HIV

Recruiting·NNational Institute of Allergy and Infectious Diseases (NIAID)·Preclinical·NCT07040319·30 enrolled

Chronic Hepatitis8 trials

A Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Glecaprevir/Pibrentasvir in Pediatric Subjects With Genotypes 1-6 Chronic Hepatitis C Virus (HCV) Infection

Completed· AbbVie logo

AbbVie·Phase 2/3·NCT03067129·129 enrolled

A Study to Evaluate the Safety and Efficacy of ABT-493/ABT-530 in Adult Post-Liver or Post-Renal Transplant Recipients With Chronic Hepatitis C Virus (MAGELLAN-2)

Completed· AbbVie logo

AbbVie·Phase 3·NCT02692703·100 enrolled

Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With Compensated Cirrhosis and With or Without Human Immunodeficiency Virus Co-Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT03235349·160 enrolled

Show 5 more trials

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT03222583·546 enrolled

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT02966795·84 enrolled

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

Completed· AbbVie logo

AbbVie·Phase 3·NCT03089944·343 enrolled

A Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults in Brazil With Chronic Hepatitis C Virus (HCV) Genotype 1 - 6 Infection

Completed· AbbVie logo

AbbVie·Phase 3·NCT03219216·100 enrolled

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Completed· AbbVie logo

AbbVie·Phase 3·NCT03069365·101 enrolled

Kidney Transplant3 trials

Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors

Completed·JJohns Hopkins University·Phase 4·NCT04575896·10 enrolled

A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney Transplantation

Completed·NNYU Langone Health·Phase 1·NCT04682509·20 enrolled

Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Kidney Transplant

Withdrawn·RRaymond T. Chung, MD·Phase 4·NCT03623568

Efficacy and Safety1 trial

Efficacy and Safety of 8-weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve Adults With HCV Genotype 1-6 and Aspartate Aminotransferase to Platelet Ratio Index (APRI) ≤1

Completed· AbbVie logo

AbbVie·Phase 3·NCT03212521·230 enrolled

Drug1 trial

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

Completed·KKirby Institute·N/A·NCT03492112·101 enrolled

6 more indications

Liver Disease1 trial

Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir

Unknown status·KKirby Institute·Phase 4·NCT03855917·30 enrolled

Randomized1 trial

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

Completed·UUniversity of Florida·Phase 3·NCT03092375·177 enrolled

Hepatitis C Virus Infection1 trial

Glecaprevir/Pibrentasvir Fixed-dose Combination Treatment for Acute Hepatitis C Virus Infection

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT04042740·45 enrolled

Real-world Study1 trial

Glecaprevir/Pibrentasvir Real-world Study in China

Unknown status·TTongji Hospital··NCT03941821·800 enrolled

Post-Traumatic Stress Disorder1 trial

Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder

Recruiting·WWhite River Junction Veterans Affairs Medical Center·Phase 2/3·NCT05637879·92 enrolled

Treatment1 trial

Elimination of HCV Through Linkage and In Prison Treatment of Incarcerated Populations (ECLIPSE)

Withdrawn·UUniversity of Maryland, Baltimore·Phase 4·NCT04235049

Sources

References

[1]
ClinicalTrials.gov — 27 trial records for Glecaprevir/Pibrentasvir. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Maviret drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Glecaprevir/Pibrentasvir compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Glecaprevir/Pibrentasvir. EMBL-EBI & Wellcome Sanger Institute.
[5]
SEC EDGAR — AbbVie company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: AbbVie

Maviret

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2027

Trials by Indication[1]

Hepatitis C8 trials

Chronic Hepatitis8 trials

Kidney Transplant3 trials

Efficacy and Safety1 trial

Drug1 trial

Liver Disease1 trial

Randomized1 trial

Hepatitis C Virus Infection1 trial

Real-world Study1 trial

Post-Traumatic Stress Disorder1 trial

Treatment1 trial

References

Drug Info

Quick Facts

Related News